Aurinia Pharmaceuticals Inc. - Form 6-K Summary
Business Context and Reporting Period
This Form 6-K was filed by Aurinia Pharmaceuticals Inc. on December 10, 2019. The filing serves to incorporate by reference a news release and underwriting agreement regarding a public offering of common shares into the company's Registration Statement on Form F-10 (File No. 333-222413).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the terms of a capital raise.
Material Changes
The primary material event disclosed is a public offering of common shares priced at US$166.7 million. This represents a significant increase in the company's capital base compared to the prior period, though specific pre-offering financial balances are not detailed in this text.
Guidance, Outlook, and Risks
The filing does not contain management commentary on future guidance, operational outlook, or specific risk factors. The document is a procedural filing to disclose the execution of the underwriting agreement dated December 9, 2019.
Investor Verification Checklist
- Verify the final closing date and total proceeds of the US$166.7 million public offering.
- Review the full Underwriting Agreement (Exhibit 99.2) for lock-up periods and underwriting fees.
- Confirm the use of proceeds as detailed in the full news release (Exhibit 99.1).
- Check the updated share count and dilution impact on existing shareholders.